Revolutionary Step in B2B: The First Verified & Trusted Pharma, Surgical & Medical Trade Automation Platform • Direct Factory Deals, Global Tenders & 7-Document Export Dossiers•Revolutionary Step in B2B: The First Verified & Trusted Pharma, Surgical & Medical Trade Automation Platform • Direct Factory Deals, Global Tenders & 7-Document Export Dossiers•
Drug & Salt Regulations

EMA Nitrosamine Impurity Assessment: Confirmatory Acceptable Intake (AI) Limits for Sartan & Metformin APIs

Mandatory regulatory update concerning N-nitrosamine and Nitrosamine Drug Substance-Related Impurities (NDSRIs) in cardiovascular and antihyperglycemic molecules (HS Code 2933.99 and HS Code 2925.29). Marketing authorization holders and API manufacturers must apply the Carcinogenic Potency Categorization Approach (CPCA).

  • Analytical Thresholds: Validated LC-MS/MS or GC-MS/MS methods capable of quantifying NDMA, NDEA, and NDSRI variants down to 10% of the compound-specific Acceptable Intake (AI) limit (typically 18–100 ng/day).
  • Excipient Control: Mandatory screening of nitrite levels in microcrystalline cellulose, povidone, and starch excipients to prevent in-situ nitrosation during granulation.

Official Source & Verification Reference

Issuing Authority: European Medicines Agency (EMA) • Reference: EMA/409815/2020-Rev.2026

Verify Official Source Document ↗